News: Portfolio 2009

NICHD/NIH TO CONDUCT CLINICAL STUDY WITH AGILE’S WEEKLY, PROGESTIN-ONLY, CONTRACEPTIVE PATCH

(continued)

About Estrogen

Estrogen may significantly decrease breast milk production. Therefore, estrogen containing contraceptives are not recommended for breast-feeding mothers. Also, in rare cases, estrogen has been linked to serious cardiovascular side effects. Women with past history of cardiovascular events or women with certain cardiovascular risk factors are recommended not to use contraceptives containing estrogen.

 

About Agile Therapeutics, Inc.

Agile Therapeutics is a high-growth, late-stage pharmaceutical company specializing in women’s health products prescribed by OB/GYNs with an initial focus on developing safer, more convenient methods of hormonal contraception. Agile’s lead product is AG200-15, an innovative, weekly, lowdose combination contraceptive patch, has the potential to become a major product in the $5

billion global hormonal contraceptive market (U.S. market $3 billion). AG200-15 is also based on Agile’s patented SKINFUSION™ technology, and utilizes the trusted hormonal combination of levonorgestrel and ethinyl estradiol. The lead product is moving into Phase 3 clinical development. Agile is privately financed, with a solid foundation for growth and backed by experienced healthcare investors, including ProQuest Investments, The Hillman Company, TL Ventures, and Novitas Capital. For more information, please visit http://www.agiletherapeutics.com.

 

 

Page: 1 2